Lixte Biotechnology Holdings is a drug discovery company that uses biomarker technology to identify enzyme targets associated with diseases and then designs compounds to attack those targets. Co.'s product pipeline is focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. Co. is developing two classes of drugs for the treatment of cancer, consisting of protein phosphatase inhibitors, designated by Co. as the LB-100 series of compounds, and histone deacetylase inhibitors, designated by Co. as the LB-200 series of compounds. Co.'s focus is on the clinical development of the LB-100 series of compounds. The LIXT stock yearly return is shown above.
The yearly return on the LIXT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LIXT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|